SRNEClinical Trials•globenewswire•
SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival
Sentiment:Positive (70)
Summary
(SRNE) IJME publication of QUELIMMUNE therapy for pediatric AKI shows a potential for hospitals to incur no out-of-pocket costs for 6 days of treatment.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by globenewswire